The effect of sumacl on fatty liver disease

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 80

Inclusion Criteria

The criteria for inclusion: Age 20-60 years of both sexes, fatty liver disease be approved by physician gastroenterologist based on the following criteria: (ultrasound, volume Alastvmtry in fiberscan and> 4 kPa (kpa) or are in the process of steatosis S1 and Alanine transferase more than 5.1 times the upper limit of normal (women and men), Body Mass Index (BMI)25-29/9), a interested in participating the plan and received written informed consent, lack of participation in other projects.
Exclusion criteria:The patient's unwillingness to continue cooperation with the
Started taking the drug during the intervening period, Change the type or dose, Change in diet or physical activity program, Weight loss more than 10% of initial body weight during the intervention , Any use of antioxidant supplements, vitamins or minerals , Less than 80% supplements delivered to the patient at baseline, Start smoking during the intervening period, Become pregnant during treatment, Surgery and psychosomatic problems during the intervention, The use of all anti-NASH (vitamin E, thiazolidinedione, UDCA gemfibrozil,), Developing other liver diseases, kidney, kidney stones, cancer, hypothyroidism or hyperthyroidism, allergies, trauma during the intervention

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alanine aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Aspartate aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Hepatic steatosis. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Using the scanning fiber 502.

Secondary Outcome Measures

Name	Time	Method
Total cholestrol. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Triglycerides. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Low density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;High density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Leptin. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Elisa.